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DObjectives: In children with cardiac disease, common indications for extracorporeal membrane oxygenation
(ECMO) include refractory cardiopulmonary resuscitation (E-CPR), failure to separate from cardiopulmonary
bypass (OR-ECMO), and low cardiac output syndrome (LCOS-ECMO). Despite established acceptance,
ECMO outcomes are suboptimal with a survival between 38% and 55%. We evaluated factors associated
with significantly increased survival in cardiac patients requiring ECMO.
Methods:We conducted a retrospective investigation of consecutive patients undergoing ECMO between 2006
and 2010. Demographic, pre-ECMO, ECMO, and post-ECMO parameters were analyzed. Neurologic outcomes
were assessed with the pediatric overall performance category scale at the latest follow-up.
Results: There were 3524 admissions, 95 (3%) of which necessitated ECMO; 40 (42%) E-CPR, 31 (33%) OR-
ECMO, and 24 (25%) LCOS-ECMO.The overall hospital survivalwas 73%. Thewithin-groups hospital survival
was 75% in E-CPR, 77% OR-ECMO and 62% LCOS-ECMO. In the multivariable logistic regression analysis,
chromosomal anomalies (odds ratio [OR], 8; 95% confidence interval [CI], 2-35), single ventricle (OR ,6; 95%
CI, 3-33), multiple ECMO runs (OR, 15; 95% CI, 4-42), higher 24-hour ECMO flows (OR, 8; 95% CI, 4-22),
decreased lung compliance (OR, 5; 95% CI, 2-16), and need for plasma exchange (OR, 5; 95% CI, 3-18)
were all significant factors associated with mortality. From the univariate analysis, a common parameter associ-
ated withmortality within all groups was intracranial hemorrhage. At 1.9 years (0.9, 2.9) of follow-up, 66%were
still alive, and 89% of survivors had normal function or only mild neurodevelopmental disability.
Conclusions: ECMO was successfully used in children with cardiac disease with 73% and 66% short- and
intermediate-term survival, respectively. The majority of the survivors had normal function or only a minimal
neurodevelopmental deficit. (J Thorac Cardiovasc Surg 2013;146:317-25)Mechanical circulatory support in children with severe car-
diac failure is most commonly performed with the use of ex-
tracorporeal membrane oxygenation (ECMO). Although
other methods of mechanical circulatory support, such as
ventricular assist devices (VADs), have emerged in the
past decade, in urgent situations and when extracorporeal
support is expected to be short-term, ECMO remains the
most common method.
In children with cardiac disease, common indications for
ECMO include failure to separate from cardiopulmonary
bypass (CPB) in the operating room (OR-ECMO), low car-
diac output syndrome (LCOS) owing to postoperative myo-
cardial dysfunction, primary myocardial disease, or
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The Journal of Thoracic and Caof therapy outweighs the potential risks of ECMO
(LCOS-ECMO), and cardiopulmonary resuscitation
(CPR) that is refractory to conventional resuscitation mea-
sures (E-CPR). LCOS was defined as signs and symptoms
of significant low cardiac output (eg, oliguria or anuria,
tachycardia, hypotension, prolonged capillary refill) and
metabolic acidosis, with or without wide arteriovenous
oxygen difference, that either worsen or do not improve
despite increased pharmacologic intervention.
Despite established acceptance, outcomes among insti-
tutions vary and overall survival has remained between
38% and 55%, even among centers with longstanding
experience.1-7
In this large institutional study,we describe the Children’s
Hospital of Pittsburgh approach to the management of car-
diac patients requiring E-CPR, OR-ECMO, and LCOS-
ECMO.We analyze factors affectingmorbidity and survival
including cardiac anatomy and physiology, cardiac surgery,
method of ECMO deployment and decannulation, and other
support variables. In addition, we describe our immediate
and intermediate-term neurologic outcomes.
METHODS
The study was performed in the cardiac intensive care unit of Children’s
Hospital of Pittsburgh, a tertiary academic center with an active heart–lungrdiovascular Surgery c Volume 146, Number 2 317
Abbreviations and Acronyms
ACT ¼ activated clotting time
APTT ¼ activated partial thromboplastin
time
CI ¼ confidence interval
CPB ¼ cardiopulmonary bypass
CPR ¼ cardiopulmonary resuscitation
ECMO ¼ extracorporeal membrane
oxygenation
E-CPR ¼ refractory cardiopulmonary
resuscitation
LCOS ¼ low cardiac output syndrome
OR ¼ odds ratio
OR-ECMO ¼ failure to separate from
cardiopulmonary bypass in the
operating room
POPC ¼ Pediatric Overall Performance
Category
VAD ¼ ventricular assist device
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Dtransplantation and mechanical circulatory support program. Approval
from the institutional review board was obtained to retrospectively review
our ECMO database and associated medical records for a 5-year period be-
tween January 2006 and December 2010.
ECMO and E-CPR Program at Children’s Hospital
of Pittsburgh
During the study period between 2006 and 2010 the structure of the car-
diac ECMO team remained the same and consisted of 2 cardiothoracic
surgeons, 3 cardiac intensivists, and 10 ECMO specialists.
All patients are supported with venoarterial ECMO, and the cannulation
site is either peripheral (neck or femoral vessels) or chest (right atrium and
aorta) depending on the surgical status of the patient. The ECMO circuit
involves a roller pump (Stockert-Shiley SIII, Sorin Group, Arvada, Colo),
with either ¼-inch or 3/8-inch diameter tubing, and an appropriate-sized
oxygenator. Circuit size is based on patient weight with patients weighing
more than 11.0 kg being supported by 3/8-inch circuits and those weighing
less than 11 kg on the ¼-inch version. Until mid-2009, both size circuits
consisted of Carmeda-coated tubing and a hollow-fiber oxygenator (Mini-
max or Affinity; Medtronic, Inc, Minneapolis, Minn). Subsequently, our
program converted from the hollow-fiber oxygenators to Bioline-coated
Quadrox iD (for<11 kg) and Poly-methyl-Pentene QuadroxD oxygenators
(for>11 kg) (Maquet, Wayne, NJ). At all times there was one circuit of
each size of tubing primed with crystalloid solution (Plasma-Lyte A;
Baxter Healthcare Corporation, Deerfield, Ill) in the cardiac intensive
care unit.
Patients whose ECMO support is initiated in the cardiac intensive care
unit are administered a loading dose of heparin (30-50 U/kg depending
on their coagulation status) 3 to 5 minutes before cannulation. The initial
pumpflow target is 120 to 160mL $kg1 $min1 and subsequently adjusted
to each patient’s requirements to maintain end-organ perfusion, normaliza-
tion of blood gases, clearance of lactic acidosis, and adequate emptying of
the failed ventricle. In general, patients with a patent Blalock-Taussig shunt
have their shunt partially clipped.Within the first hour after cannulation, and
once ECMO flow goals are met, inotropic agents are discontinued, ventila-
tory settings are changed to ‘‘ECMO resting ventilatory settings’’ including
a positive end-expiratory pressure of 8 to 10 cm H2O, inspired oxygen318 The Journal of Thoracic and Cardiovascular Surgfraction of 0.3, tidal volume of 4 to 5 mL/kg, peak inspiratory pressure of
25 cmH2Oor less, and ventilation rate of 10 to 14 breaths/min. Temperature
is maintained between 36C and 37C for noncardiac arrest patients and
34C and 36C after cardiac arrest for 24 hours. Cannula position is con-
firmed by chest radiograph and echocardiography. Sedatives and analgesics
are started only after patients have shown satisfactory neurologic status and
include dexmedetomidine and fentanyl to maintain comfort and maintain
a mild to moderate level of sedation. Movement is generally allowed so
long as there is no significant bleeding and it does not interfere with
ECMO mechanics. When muscle relaxation is needed, the drug of choice
is cisatracurium. Broad-spectrum antibiotics with cefipime are started. Di-
uretics are given to achieve negative fluid balance and, when not sufficient,
slow intermittent ultrafiltration is used. For the ultrafiltration, a hemofilter is
placed in series with the ECMO circuit and plasma water is removed as
needed and as tolerated to achieve an approximate 5 to 10mL negative fluid
balance per hour.
Subsequent monitoring includes arterial blood gases and electrolytes
every hour until stable and then every 2 to 4 hours, hemoglobin, platelets,
and lactic acid level every 4 to 6 hours, creatinine level every 12 hours,
chest radiograph 1 to 2 times daily, blood cultures and head ultrasound
daily, and an initial electroencephalogram.
After the initial heparin loading, further anticoagulation is achieved
with continuous infusion of unfractionated heparin administered via the
venous limb of the circuit and is started 12 to 18 hours after cannulation.
Coagulation status is evaluated using a multifactorial approach with both
point-of-care and conventional laboratory testing. All point-of-care mea-
surements were obtained using the Hemacron Jr. Signature Elite (Interna-
tional Technidyne Corporation, Edison, NJ), which includes activated
clotting time (ACT) and whole blood activated partial thromboplastin
time (APTT) every 1 hour. Conventional laboratory testing with plasma
APTT, prothrombin time, international normalized ratio, and fibrinogen
is monitored every 4 hours. Antithrombin III level, antifactor Xa for unfrac-
tionated heparin, and thromboelastogram with and without heparinase are
obtained every 12 to 24 hours. The general target guidelines for anticoagu-
lation include an ACT of 170 to 200 seconds, an APTT of 70 to 100 sec-
onds, antifactor Xa of 0.35 to 0.65 mg/mL, international normalized ratio
less than 2, and fibrinogen greater than 150. Hematocrit is usually kept
greater than 30 and platelets greater than 100,000/cm3. Heparin dosing
adjustment is based on the results of ACT, antifactor Xa level, APTT,
and thromboelastogram and taking into consideration clinical judgment.
One of themost important steps in this process is the assessment of read-
iness for decannulation. This starts almost immediately after cannulation
and subsequently is performed at a minimum of twice daily. The cardiac
evaluation includes an echocardiogram to assess ventricular function,
rule out any left ventricular and atrial distention, valvular insufficiency,
and pericardial effusion and to evaluate for any residual defects in patients
who had undergone cardiac surgery. Pulmonary assessment includes mea-
surement of pulmonary compliance, and patients with significantly de-
creased compliance routinely receive exogenous surfactant. If left-sided
structures are distended and associated with pulmonary edema, a low-
dose epinephrine infusion is started to improve contractility. If no benefit
is noted, then a left atrial or ventricular vent is inserted or a balloon atrial
septostomy is performed in the cardiac catheterization laboratory. These
interventions are performed the same day and before pulmonary edema
worsens or pulmonary hemorrhage develops. The echocardiograms are
performed mostly by the cardiac intensivists and are usually very brief
(<1-2 minutes) and performed with minimal ECMO flows (20-30 mL/
kg) while hemodynamic parameters are observed for any deterioration. If
no significant deterioration is noted, that is, low systemic blood pressure
and or high filling pressures, and ventricular function and pulmonary
compliance appear adequate, including arterial pulsatility, a bridge is
placed between the arterial and venous cannulas and the patient is isolated
from the ECMO circuit. At the same time mechanical ventilation is
optimized for spontaneous circulation, a low-dose infusion of epinephrineery c August 2013
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Dat 0.05 mg $ kg1 $min1 andmilrinone at 0.5 mg $ kg1 $min1 are started
and the patient is decannulated within 1 hour if no hemodynamic decline or
significant metabolic acidosis occurs.
If several attempts to wean from ECMO are unsuccessful and no further
early cardiac recovery is anticipated, evaluation is started to convert from
ECMO to a VAD and subsequently to heart transplantation if needed. Al-
though during the initial study period some patients were converted directly
from ECMO to heart transplantation, in general we no longer practice this
approach. This decision was based on our encouraging results with the use
of VADs and the rather inferior results with the former approach. Transition
from ECMO to VAD serves as a bridge to heart transplantation or to myo-
cardial recovery and therefore in general patients who have an absolute
contraindication to heart transplantation are not candidates for a VAD
either.Data Collection and Categorization
Data collected included demographic information, chromosomal and
major noncardiac structural abnormalities, cardiac diagnosis and surgery,
Aristotle complexity score, need for reoperation, CPR and ECMO parame-
ters, ventilatory support, surrogates of cardiac function and cardiac output,
inotropic support, bloodstream infections, complications, and long-term
neurologic outcomes.8 The primary outcome variable was survival to dis-
charge from the hospital to either home or another facility.
Patients were divided into 3 major categories: E-CPR, OR-ECMO, and
LCOS-ECMO. Subsequently and because of the diversity of cardiac
lesions and physiology, patients were grouped into the following sub-
groups: (1) single-ventricle lesions (patients with 1 functional ventricle);
(2) 2-ventricle lesions; (3) primary myocardial disease (including patients
with heart transplantation); and (4) primary pulmonary hypertension.
Complications during ECMO were categorized as follows: (1) brain in-
jury (clinical or electroencephalographic seizures, significant central ner-
vous system hemorrhage including epidural or subdural hematoma,
subarachnoid hemorrhage and greater than grade I intraventricular hemor-
rhage, and infarction or diffuse ischemic changes based on ultrasound or
computed tomographic scan); (2) renal injury (serum creatinine 1.5
mg/dL or dialysis use via hemodialysis, continuous venovenous hemodial-
ysis or hemofiltration); (3) bloodstream bacterial infection; (4) respiratory
complications (ventilator-associated pneumonia, acute respiratory distress
syndrome, pulmonary hemorrhage, or pneumothorax); (5) cardiac compli-
cations (new arrhythmias that required treatment, CPR, and inotropic sup-
port); (6) gastrointestinal complications (gastrointestinal hemorrhage or
hyperbilirubinemia [defined as serum-conjugated bilirubin 2 mg/dL or
total bilirubin 15 mg/dL]); (7) bleeding (cannulation or surgical site
bleeding, hemothorax, and hemopericardium requiring intervention); (8)
mechanical circuit complications (air emboli, thrombus formation in the
circuit, breaks or leaks developing in any part requiring circuit change,
and oxygenator failure).
Ventricular functionwas gradedon the basis of available echocardiograms
within 24 hours before and after ECMOdecannulation. Function was graded
as normal¼ 1,mildly depressed¼ 2,moderately depressed¼ 3, and severely
depressed¼ 4.
The cardiac E-CPR team consists of an attending cardiac surgeon and
fellow, an attending cardiac intensivist and fellow, a perfusionist, and nurs-
ing staff. The decision to activate the cardiac E-CPR team is made by the
bedside cardiac intensive care unit physician, and it is usually initiated if
there is failure of return of spontaneous circulation after 1 round of resus-
citation drugs. However, owing to time logistics related to the preparation
for ECMO, cannulation does not occur until after 3 rounds of resuscitation
drugs are given. If spontaneous circulation is witnessed beforehand, then
cannulation is aborted. Resuscitation drugs routinely include epinephrine,
sodium bicarbonate, and calcium chloride every 3 minutes. Chest compres-
sion quality is vigorously monitored via the arterial line or the telemetry
electrocardiographic tracing if a reliable arterial line is not available. The
surface electrocardiographic amplitude is used as a surrogate of chestThe Journal of Thoracic and Cacompression depth, and the person performing chest compressions is under
sterile attire to avoid any significant interruption during ECMO
cannulation.
CPR data included first documented rhythm before CPR, first pulseless
rhythm, duration of CPR, intubation status before CPR, resuscitation drugs,
and worst pH and lactate levels within 6 hours before CPR.
ECMO flows and temperature were assessed at 4 and 24 hours after
cannulation. Worst lactic acid level and pH were recorded within 6 hours
before and after cannulation. Peak creatinine and bilirubin levels were re-
corded during ECMO. Inotropic support after ECMO was defined on the
basis of the need for epinephrine during the first hour after decannulation.
Patent ductus arteriosus ligation, left atrial vent, balloon atrial septos-
tomy, and any major noncardiac operations during ECMOwere considered
invasive interventions and not cardiac reoperations.
To assess global neurologic status, we used the Pediatric Overall Perfor-
mance Category (POPC) scale.9 This score was assigned to survivors at
time of the latest outpatient follow-up if adequate neurodevelopmental
information was available in medical records.
Definitions
ECMO recovery: presence of ‘‘native’’ circulation for 48 hours after
decannulation. ECMO recannulation: second ECMO run within 48 hours
of decannulation.Multiple ECMO runs: 2 or more runs during hospitaliza-
tion. Twenty-eight–day survival: alive at 28 days after initiation of ECMO.
ECMO survival: alive at time of hospital discharge or transfer to another
facility; Cardiac surgery: cardiac surgery that occurred during the same
admission as ECMO use.
Statistical Analysis
If a patient had multiple ECMO runs, only the first ECMO run was
included in the analysis. Demographics, pre-ECMO, ECMO, and post-
ECMO factors and complications were compared between survivors and
nonsurvivors for each major ECMO category separately. Data are pre-
sented as frequency (n) with proportion (percent) and median with inter-
quartile range. Categorical data were compared with Fisher’s exact test
or the c2 test where appropriate and continuous data with the Wilcoxon
test for 2-group comparison or Kruskal-Wallis test for 3-group comparison.
Two separate multivariable logistic regression models were developed
to identify factors independently associated with mortality. The logistic
regression analysis included all ECMO patients, and the ECMO subgroups
served as independent variables. The first model investigated the influence
of baseline demographic and pre-ECMO factors whereas the second model
analyzed the association of variables during ECMO support including com-
plications. Variables entered themultivariate model only if their probability
value from the univariate analysis was 0.1 or less. Variables containing con-
tinuous data were retained in the model only if assumption of linearity was
met. Variables not meeting the linearity assumption were divided into cat-
egories and included in the model as categorical variables. Depending on
the variable, values were then dichotomized to either below or above the
25th or 75th percentile among patients who died. Each model was assessed
for fitness against actual outcomes with the Hosmer-Lemeshow goodness-
of-fit test. A P value>.05 suggested that the model was fit to the data well.
Additionally, a correlation matrix was performed to evaluate for multicol-
linearity, and variables with statistically significant medium or strong
correlation were excluded from the multivariate model. Analysis was
performed with JMP version 9.0 (SAS Institute, Inc, Cary, NC).RESULTS
Study Population
During the study period from January 2006 to December
2010, there were a total of 3524 admissions to the cardiac
intensive care unit, 95 (2.7%) of which required 103rdiovascular Surgery c Volume 146, Number 2 319
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DECMO runs. Tables 1 to 3 demonstrate the demographic
information of these patients. There were 40 (42%) patients
in the E-CPR group, 31 (33%) in the OR-ECMO, and 24
(25%) in the LCOS-ECMO. The overall survival to hospital
discharge was 73% and at the time of study completion, at
a median time of 1.9 years (0.9, 2.9) from discharge, 63
patients (66%) were still alive.
Pre-ECMO and ECMO Factors
Tables 2 to 4 show a comparison of the pre-ECMO and
ECMO support variables between survivors and
nonsurvivors.
E-CPR group. All E-CPR patients were receiving chest
compressions at the time of ECMO cannulation. More non-
survivors required pre-ECMO high-frequency oscillatory
ventilation and nitric oxide and a higher epinephrine dose.
Additionally, nonsurvivors had a lower pH and a higher lac-
tate level (Table 2). The 3 nonsurvivors with chromosomal
defects all had significant abnormalities including methyl-
tetrahydrofolate reductase deficiency and development of
multiple systemic thromboemboli, trisomy 21 with signifi-
cant midfacial hypoplasia and B-cell immunodeficiency,
and futile mitochondrial DNA mutation.
OR-ECMO group. Nonsurvivors had higher ECMO flows
at 4 and 24 hours, had longer ECMOduration, and after dec-
annulation they had worse ventricular function and required
a higher epinephrine dose (Table 3).
LCOS-ECMO group. No difference was noted in the pre-
ECMO variables. During ECMO, nonsurvivors had higher
ECMO flows at 24 hours, more nonsurvivors had a lactate
level of more than 5, and there was a trend toward moreTABLE 1. Demographic features of all ECMO patients
E-CPR
S NS P
N (%) 30 (75.0) 10 (25.0) 24
Age, d 84 (19, 870) 13 (7, 150) .03 10
Weight, kg 4.9 (3.4, 9.9) 2.9 (2.5, 5.0) .01 3.6
Gestational age, wk 42 (40, 48) 40 (38, 42) .08 38
Sex, M (%) 17 (57) 8 (80) .17 14
Cardiac diagnosis .005
SV, n (%) 4 (13) 7 (70) .001 7
2-V, n (%) 16 (53) 1 (10) .04 16
PMD, n (%) 8 (27) 2 (20) 1
PPHTN, n (%) 2 (7)
Cardiac surgery n (%) 14 (47) 4 (40) 1.00 24
Aristotle level, n (%) .11
1 1 (7) 0 2
2 3 (21) 0 4
3 3 (21) 0 4
4 7 (50) 4 (100) 14
Chromosomal anomalies, n (%) 3 (10) 3 (30) 0.15 4
ECMO, Extracorporeal membrane oxygenation; E-CPR, refractory cardiopulmonary resusc
room; LCOS, low cardiac output syndrome; S, survivors; NS, nonsurvivors; SV, single v
pulmonary hypertension.
320 The Journal of Thoracic and Cardiovascular Surgnonsurvivors receiving plasma exchange (Table 4). Addi-
tionally, the LCOS-ECMO group had significantly longer
ECMO duration (87 hours [59, 191]) than the E-CPR group
(50 hours [29, 97] [P¼ .02]) than the OR-ECMO group (38
hours [24, 84] [P ¼ .007]).
ECMO Complications
Table 5 illustrates the complications between survivors
and nonsurvivors.
E-CPR. Overall, nonsurvivors had significantly more
complications than survivors. Among the complications,
intracranial hemorrhage had the highest incidence.
OR-ECMO. All 7 nonsurvivors had at least 1 complication
each. None of the survivors had intracranial hemorrhage.
LCOS-ECMO. All nonsurvivors had at least 1 complica-
tion each. Intracranial hemorrhage was seen in 33% of
nonsurvivors versus 0% in survivors (P ¼ .005). Further-
more, more nonsurvivors experienced oxygenator failure
(Table 5).
Overall, among all study patients, 56% had at least
1 complication. Neurologic injury was detected in 21
(22%) patients, with intracranial hemorrhage in 11 (12%)
and cerebral infarct in 6 (6%). Significant residual cardiac
defects needing surgical repair were observed in only 2 of
the 62 (3%) surgical cases.
Multivariable Logistic Regression Analysis of
Factors Associated With Mortality
The results of the multivariable logistic regression
models are shown in Table 6. Corrected gestational age,
ECMO flows at 4 hours, worst pH, and lactate in the firstOR-ECMO LCOS-ECMO
S NS P S NS P
(77.0) 7 (23.0) 15 (62.5) 9 (37.5)
(6, 176) 22 (5,36) .68 16 (5, 5y) 140 (2, 912) .76
(3.0, 5.0) 2.5 (2.0,3.0) .01 3.4 (3.2, 16.1) 3.8 (3.0, 15.2) .90
(36, 39) 36 (33,40) .18 38 (37, 41) 37 (34, 39) .10
(58) 4 (57) 1.00 9 (60) 5 (56) .83
.64 .25
(29) 3 (43) 2 (13) 3 (33)
(67) 4 (57) 6 (40) 5 (56)
(4) 0 6 (40) 1 (11)
1 (7) 0
(100) 7 (100) 1.00 6 (40) 7 (78) .10
.67 .88
(8) 0 0 0
(17) 2 (29) 1 (17) 0
(17) 2 (29) 2 (33) 3 (43)
(58) 3 (43) 3 (50) 4 (57)
(17) 2 (29) .59 0 5 (56) .002
itation;OR-ECMO, failure to separate from cardiopulmonary bypass in the operating
entricle; 2-V, two ventricles; PMD, primary myocardial disease; PPHTN, primary
ery c August 2013
TABLE 2. Pre-ECMO and ECMO variables in the 40 E-CPR patients
Survivors
(n ¼ 30)
Nonsurvivors
(n ¼ 10) P
Pre-ECMO
Pre-ECMO/pre-CPR VF 3 (2, 4) 4 (3, 4) .30
Pre-ECMO therapies .12
Nitric oxide, n (%) 8 (27) 5 (50) .24
HFOV, n (%) 0 1 (10) .25
CPR duration, min 40 (25, 50) 37 (35, 50) .84
Categorized ABG pH
pH 7.35 (7.03, 7.43) 7.23 (7.11, 7.49) .95
pH<7.21, n (%) 10 (33) 4 (40) .71
Lactate, mmol/L 5 (3, 15) 12 (3, 19) .32
Lactate>5, n (%) 13 (46) 6 (67) .47
Epinephrine,
mg $ kg1 $ min1
0.09 (0.01, 0.18) 0.2 (0.07, 1.0) .05
ECMO
Cannulation site .72
Chest, n (%) 15 (50) 4 (40)
Neck, n (%) 15 (50) 6 (60)
ECMO flow at 4 h,
mL $ kg1 $ min1
132 (100, 156) 148 (105, 185) .28
ECMO flow at 24 h,
mL $ kg1 $ min1
129 (104, 143) 135 (115, 164) .43
Categorized ABG pH
pH 7.5 (7.35, 7.55) 7.3 (7.18, 7.33) .001
pH<7.21, n (%) 0 3 (30) .01
Lactate, mmol/L 3 (2, 5) 13 (7, 23) <.001
Lactate>5, n (%) 5 (17) 7 (78) .003
Temperature at 4 h 34.8 (34.0, 35.4) 35.5 (34.6, 36.1) .15
Temperature at 24 h 35.6 (34.7, 36.3) 35.6 (34.0, 36.6) 1.00
Ventilatory support
Rate, breaths/min 15 (10, 16) 11 (10, 18) .56
PIP, cm H2O 24 (22, 28) 26 (20, 32) .51
PEEP, cm H2O 8 (6, 10) 9 (5, 10) .93
Tidal volume, mL/kg 7 (4, 8) 7 (3, 10) .80
Compliance,
mL $ kg1 $ cm H2O
1
0.4 (0.3, 0.5) 0.3 (0.2, 0.6) .58
Fluid balance, mL/kg 16 (76, 94) 20 (220, 133) .82
Plasma exchange, n (%) 4 (13) 3 (30) .33
ECMO duration, h 53 (29, 98) 48 (28, 102) .96
Post-ECMO VF 2 (1, 3) 3 (2, 4) .09
Post-ECMO epinephrine,
mg $ kg1 $ min1
0.07 (0.05, 0.19) 0.1 (0.08, 1.00) .19
Redo cardiac surgery,
n (%)*
1 (7)y 0 1.00
Invasive interventions,
n (%)
3 (10) 1 (10) 1.00
ECMO, Extracorporeal membrane oxygenation; E-CPR, refractory cardiopulmonary
resuscitation; CPR, cardiopulmonary resuscitation; VF, ventricular function; HFOV,
high-frequency oscillatory ventilation; ABG, arterial blood gas; PIP, peak inspiratory
pressure; PEEP, positive end-expiratory pressure. *Percent among patients who had
cardiac surgery. yEnlargement of fenestrated ventricular septal defect.
TABLE 3. Pre-ECMO and ECMO variables in the 31 OR-ECMO
patients
Survivors
(n ¼ 24)
Nonsurvivors
(n ¼ 7) P
Pre-ECMO
Pre-ECMO VF 2 (1, 3) 3 (1, 3) .82
Pre-ECMO therapies
Nitric oxide, n (%) 7 (30) 4 (57) .16
ECMO
ECMO flow at 4 h,
mL $ kg1 $ min1
142 (110, 152) 205 (140, 317) .03
ECMO flow at 24 h,
mL $ kg1 $ min1
97 (46, 139) 212 (144, 318) .002
Categorized ABG pH
pH 7.43 (7.32, 7.52) 7.38 (7.33, 7.47) .60
pH<7.21, n (%) 1 (4) 0 1.00
Lactate, mmol/l 4 (2, 6) 3 (3, 5) .74
Lactate>5, n (%) 7 (29) 1 (14) .64
Ventilatory support
Rate, breaths/min 12 (10, 22) 10 (10, 12) .14
PIP, cm H2o 24 (22, 26) 24 (20, 26) .53
PEEP, cm H2o 8 (6, 10) 5 (5, 10) .33
Tidal volume, mL/kg 6 (5, 8) 5 (2, 7) .09
Compliance,
mL $ kg1 $ cm H2O
1
0.4 (0.3, 0.5) 0.2 (0.1, 0.5) .16
Fluid balance, mL/kg 4 (133, 91) 70 (155, 2) .38
Plasma exchange, n (%) 0 0
ECMO duration, h 32 (23, 63) 134 (25, 192) .02
Post-ECMO VF 1 (1, 2) 3 (2, 4) .005
Post-ECMO epinephrine,
mg $ kg1 $ min1
0.12 (0.05, 0.11) 0.21 (0.20, 0.21) .008
Redo cardiac surgery,
n (%)
0 1 (14)* .22
Invasive interventions,
n (%)
0 0
ECMO, Extracorporeal membrane oxygenation; OR-ECMO, failure to separate from
cardiopulmonary bypass in the operating room; VF, ventricular function; ABG, arte-
rial blood gas;PIP, peak inspiratory pressure; PEEP, positive end-expiratory pressure.
*Tricuspid valve repair in a Norwood patient.
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D6 hours of ECMOwere excluded from the analysis owing to
multicollinearity with weight, ECMO flows at 24 hours, pH
less than 7.21, and lactate greater than 5, respectively.
Model 1 revealed that having single ventricle, chromo-
somal/structural abnormalities, and multiple ECMO runs
increased the likelihood of mortality significantly. In modelThe Journal of Thoracic and Ca2, ECMO flows at 24 hours, lung compliance, and plasma
exchange increased the likelihood of mortality.
The overall incidence of mortality in patients with single
ventricle was 50%, in patients with chromosomal/structural
abnormalities 59%, and in patients who had plasma
exchange 57%.Other ECMO and Neurologic Outcomes
Table 7 summarizes the overall ECMO outcomes includ-
ing short- and long-term neurodevelopmental outcomes.
Only 3 (3%) patients required ECMO recannulation.
Among the 7 (7%) patients who were transitioned to
a VAD, 5 (71%) survived to discharge. Four patients
received heart transplantation directly from ECMO, 2
(50%) of whom died. One was a neonate with complex
heart disease who required ECMO for LCOS. After she
received heart transplantation she had a cardiac arrest
requiring a second ECMO run. Care was withdrawn owingrdiovascular Surgery c Volume 146, Number 2 321
TABLE 4. Pre-ECMO and ECMO variables in the 24 LCOS-ECMO
patients
Survivors
(n ¼ 15)
Nonsurvivors
(n ¼ 9) P
Pre-ECMO
Pre-ECMO VF 2 (2, 3) 3 (1, 4) .89
Pre-ECMO therapies .67
Nitric oxide, n (%) 8 (53) 3 (33) .42
HFOV, n (%) 1 (7) 1 (11) 1.00
Categorized ABG pH
pH 7.36 (7.26, 7.45) 7.35 (7.26, 7.42) 1.00
pH<7.21, n (%) 1 (7) 1 (11) 1.00
Lactate, mmol/l 5 (2, 10) 8 (5, 11) .23
Lactate>5, n (%) 7 (47) 6 (67) .42
Epinephrine,
mg $ kg1 $ min1
0.1 (0.05, 0.15) 0.13 (0.07, 0.20) .48
ECMO
Cannulation site .67
Chest, n (%) 6 (40) 5 (56)
Neck, n (%) 9 (60) 4 (44)
ECMO flow at 4 h,
mL $ kg1 $ min1
94 (76, 155) 147 (104, 160) .28
ECMO flow at 24 h,
mL $ kg1 $ min1
94 (59, 151) 161 (130, 185) .01
Categorized ABG pH
pH 7.49 (7.28, 7.56) 7.52 (7.32, 7.52) .9
pH<7.21, n (%) 1 (7) 0 1.00
Lactate, mmol/L 2 (2, 4) 4 (2, 8) .12
Lactate>5, n (%) 0 4 (44) .01
Ventilatory support
Rate, breaths/min 12 (10, 16) 10 (10, 13) .62
PIP, cm H2O 26 (18, 30) 25 (23, 26) .63
PEEP, cm H2O 8 (6, 10) 10 (6, 10) .72
Tidal volume, mL/kg 6 (2, 7) 3 (2, 5) .35
Compliance,
mL $ kg1 $ cm H2O
1
0.3 (0.2, 0.5) 0.2 (0, 0.24) .09
Fluid balance, mL/kg 20 (106, 11) 20 (17, 58) .87
Plasma exchange, n (%) 2 (13) 5 (56) .06
ECMO duration, h 62 (32, 85) 144 (120, 237) .20
Post-ECMO VF 2 (1, 3) 2 (2, 4) .60
Post-ECMO epinephrine,
mg $ kg1 $ min1
0.08 (0.05, 0.10) 0.05 (0.02, 0.08) .24
Cardiac surgery, n (%) 1 (7)* 1 (11)y 1.00
Invasive interventions,
n (%)
2 (13) 3 (33) .25
ECMO, Extracorporeal membrane oxygenation; LCOS, low cardiac output syn-
drome; VF, ventricular function; HFOV, high frequency oscillatory ventilation;
ABG, arterial blood gas; PIP, peak inspiratory pressure; PEEP, positive end-
expiratory pressure. *Not a redo cardiac surgery: Double-inlet left ventricle 
double-outlet right ventricle, restrictive ventricular septal defect requiring defect
enlargement. yNot a redo cardiac surgery: status post Fontan 2 years prior, now
with severe plastic bronchitis, requiring takedown of Fontan and placement of a Bla-
lock-Taussig shunt.
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with dilated cardiomyopathy who was placed on ECMO
after cardiac arrest. Three weeks after receiving heart trans-
plantation he died of viral septicemia.
At the latest outpatient follow-up, 1.9 years (0.9, 2.9)
from hospital discharge, 56 patients (81%) had normal to
mild neurologic disability, and 6 patients (9%) died.322 The Journal of Thoracic and Cardiovascular SurgDISCUSSION
Despite increasing utilization and experience with
ECMO support in children with cardiac failure, survival
for over a decade has remained unchanged and in the order
of 38% to 55%.1-7 The reason for the lack of improved
survival is likely multifactorial and among others includes
use of ECMO for patients with increasingly more
complex cardiac and associated noncardiac defects;
ECMO management and complications during ECMO;
perhaps delay in initiating ECMO and delay in ECMO
decannulation; CPR management; and in patients after
cardiac surgery, significant residual cardiac defects. In the
current study, however, we were able to demonstrate
a considerable in-hospital and intermediate-term survival,
reaching 73% and 66%, respectively. This survival was
observed in all of the studied groups, but perhaps of most
interest was the survival in the E-CPR group, where short-
term survival was 75% and long-term survival 70%. This
is significantly different from what has recently been dem-
onstrated by some other recent studies in which the reported
survival ranged from 34% to 51%.3,4,10,11Predictors of Mortality
Given the diversity of cardiac disease, indications for
ECMO, and complexity of ECMO variables, different anal-
yses were performed to identify factors that may be associ-
ated with mortality. In the multivariable logistic regression
models, which included all study patients, indication for
ECMO, that is, E-CPR, OR-ECMO, and LCOS-ECMO,
did not appear to be independently associated with mortal-
ity. Chromosomal anomalies along with having single
ventricle and multiple ECMO runs were all significant
factors associated with mortality. This increased risk of
mortality with chromosomal abnormalities has been shown
by others.3 The survival in patients with single ventricle was
50% and, although lower than other patients in our study, it
is comparable with what has been reported by Morris1
(37%) Chan5 (36%), and their associates. Patients with
multiple ECMO runs had a survival of only 29% and a mor-
tality odds ratio of 15. This is consistent with other studies
in which the survival in patients requiring multiple ECMO
runs ranged from 5% to 38%.1,2
In the second model of logistic regression, high ECMO
flows at 24 hours, decreased lung compliance, and plasma
exchange were all independently associated with increased
mortality. Although initial support with higher ECMOflows
is required for myocardial recovery and optimal end-organ
perfusion, persistent need for higher flows may represent
ongoing myocardial dysfunction. In reference to plasma
exchange, it is unclear from our data whether the procedure
itself contributed to the increased mortality or whether
plasma exchange was used more often in the ‘‘sickest’’ of
patients.ery c August 2013
TABLE 5. Complications during ECMO
E-CPR OR-ECMO LCOS-ECMO
S (n ¼ 30) NS (n ¼ 10) P S (n ¼ 24) NS (n ¼ 7) P S (n ¼ 15) NS (n ¼ 9) P
Any complications, n ¼ patients (%) 14 (47) 8 (80) .08 8 (33) 7 (100) .002 7 (47) 9 (100) .009
Brain injury 7 (23) 6 (60) .052 1 (4) 3 (43) .02 0 4 (44) .01
Seizures, n (%) 3 (10) 0 .55 1 (4) 2 (29) .11 0 0
CNS bleeding, n (%) 2 (7) 4 (40) .02 0 2 (29) .04 0 3 (33) .04
CNS infarct, n (%) 2 (7) 2 (20) .25 0 1 (14) .22 0 1 (11) .37
Renal dysfunction 6 (20) 1 (10) .64 6 (25) 1 (14) 1.0 4 (27) 3 (33) 1.00
Bacteremia, n (%) 3 (10) 0 .54 1 (4) 1 (14) .40 0 0
ECMO support
Oxygenator failure 2 (7) 0 1.0 2 (8) 0 1.0 0 4 (44) .01
Circuit thrombus 3 (10) 0 .56 3 (12) 0 1.0 3 (20) 3 (33) .63
Cannula, surgical site, other bleeding 4 (13) 1 (10) 1.0 4 (17) 1 (14) 1.0 2 (13) 5 (56) 0.06
Respiratory
Pulmonary hemorrhage 0 0 0 0 0 2 (22) .13
Pneumothorax 0 1 (10) .25 1 (4) 0 1.0 0 1 (11) .37
Cardiac
Arrhythmias 0 0 1 (4) 0 1.0 0 1 (11) .37
CPR 0 0 0 0 0 0
Inotropes 3 (10) 1 (10) 1.0 3 (12) 1 (14) 1.0 1 (7) 3 (33) .13
Gastrointestinal
Hyperbilirubinemia 4 (13) 1 (10) 1.0 1 (4) 0 1.0 3 (20) 3 (33) .63
ECMO, Extracorporeal membrane oxygenation; E-CPR, refractory cardiopulmonary resuscitation;OR-ECMO, failure to separate from cardiopulmonary bypass in the operating
room; LCOS, low cardiac output syndrome; S, survivors; NS, nonsurvivors; CNS, central nervous system; CPR, cardiopulmonary resuscitation.
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The E-CPR group had a 75% survival to hospital dis-
charge. The most important factors associated with
decreased survival were cardiac arrest in patients with single
ventricle, younger age, higher epinephrine dose beforeTABLE 6. Multivariable logistic regression models showing
predictors of mortality
OR 95% CI P
Model 1: Baseline and pre-ECMO factors*
Weight 0.8 .36
Cardiac diagnosis (SV)y 5.9 3.2-33.1 .02
Chromosomal/structural abnormalities 8.3 2.5-35.0 .005
Pre-ECMO therapiesz 1.4 .60
Epinephrine dose>0.2 mg $ kg1 $ min1 2.1 .14
Multiple ECMO runs 15.3 4.5-42.3 <.001
Model 2: ECMO factorsx
ECMO flow at 24 h>185 mL $ kg1 $ min1 8.4 4.0-21.8 .005
pH<7.21 0.8 .37
Lactate>5 3.2 .09
Lung compliance<0.21 mL $ kg $ cm1 H2O
1 5.2 2.5-16.1 .02
Creatinine>1.2 mg/dL 2.0 .14
CNS infarct 0.1 .78
CNS hemorrhage 1.5 .23
Plasma exchange 5.1 3.4-18.0 .03
ECMO duration>180 h 0.2 .66
In all ECMO patients, parameters were adjusted for multicollinearity.OR,Odds ratio;
CI, confidence interval; ECMO, extracorporeal membrane oxygenation; SV, single
ventricle; CNS, central nervous system. *Model 1 characteristics: n ¼ 91; Hosmer-
Lemeshow P ¼ .82. yTwo-ventricle versus single ventricle. Primary myocardial
disease and pulmonary hypertension were classified as a 2-ventricle parameter to
run the regression analysis. zHigh frequency oscillation and nitric oxide. xModel 2
characteristics: n ¼ 93; Hosmer-Lemeshow P ¼ 0.91.
The Journal of Thoracic and Caarrest, significant metabolic acidosis during the early
ECMOcourse, and development of intracranial hemorrhage.
The duration of CPR did not differ between survivors and
nonsurvivors, as other studies have shown,3,10 but contrary
to other reports, ECMO duration did not differ either. In
patients with single ventricle, E-CPR had a survival of
only 36%, which is comparable with recent reported
Extracorporeal Life Support Organization outcomes.5
In an attempt to identify factors that could be contributing
to the increased E-CPR survival in the current study, we com-
pared our results with the findings from 2 other notable E-
CPR studies. The first study was by Kane and associates,3
who reported their institutional findings in 172 patients
from 1995 to 2008 and had a survival of 51%; the second
was by Chan and colleagues,5 who reported the Extracorpo-
real Life Support Organization E-CPR outcomes in 492
patients from 1992 to 2005 and had a survival of 42%. Over-
all, it appears that in the current study, therewere significantly
fewer complications, for example, bleeding, sepsis, and renal
insufficiency, less acidosis, improved, higher initial ECMO
flows, and significantly decreased ECMO duration. We can
only speculate whether these differences are true and how
they influence survival. Some of the complications, such as
central nervous system infarct and renal failure, are to some
extent related to the quality of CPR before ECMO, including
minimally interrupted chest compressions during ECMO
cannulation,which necessitates a technically skilled cannula-
tion team.Beyond this, however,we strongly believe in deliv-
ering higher initial ECMO flows and thus improved cardiacrdiovascular Surgery c Volume 146, Number 2 323
TABLE 7. Short- and intermediate-term ECMO and
neurodevelopmental outcomes
E-CPR
(n ¼ 40)
OR–ECMO
(n ¼ 31)
LCOS–ECMO
(n ¼ 24) P
Hospital survival, n (%) 30 (75.0) 24 (77.0) 15 (62.5) .40
28-Day survival, n (%) 31 (77.5) 26 (81.0) 17 (71.0) .51
ECMO recovery, n (%) 25 (62.5) 26 (81.0) 15 (62.5) .10
ECMO recannulation 1 (2.5) 2 (6.0) 0 .47
ECMO to VAD, n (%) 4 (10.0) 0 3 (12.5) .11
Hospital survival,
n (%)
4 (100) 1 (33)
VAD to recovery, n 2 1
VAD to transplant, n 2
ECMO to transplant,
n (%)
2 (5) 0 2 (8) .28
Hospital survival,
n, (%)
1 (50) 1 (50)
Multiple ECMO runs,
n (%)
2 (5) 3 (10) 2 (8) .69
2–runs, n 2* 2y 2z
3–runs, n 1x
Neurodevelopmental
outcomes
POPC scale at latest
follow-up
Interval time from
ECMO, y
1.7 (1, 4) 2 (1, 3) 1.7 (0.6, 3) .63
Survival, n (%) 28 (70) 22 (71) 13 (54) .30
Good-mild
disability, n (%)
24 (80) 20 (83) 12 (80) 1.00
Moderate-severe
disability, n (%)
4 (13) 2 (8) 1 (7) .77
Death, n (%) 2 (7) 2 (8) 2 (13) .75
ECMO, Extracorporeal membrane oxygenation; E-CPR, refractory cardiopulmonary
resuscitation;OR-ECMO, failure to separate from cardiopulmonary bypass in the op-
erating room; LCOS, low cardiac output syndrome; VAD, ventricular assist device;
POPC, Pediatric Overall Performance Category scale. *One patient survived and 1
died. yBoth died. zBoth patients died. One died after being transitioned to VAD
and the other after a heart transplant. xSurvived.
Congenital Heart Disease Chrysostomou et al
C
H
Doutput, particularly after cardiac arrest when end organs in-
cluding the myocardium have likely had a degree of hypoxic
injury. Last and perhaps equally important, we speculate that
the shorter ECMOduration plays a role in this. As outlined in
our Methods section, another strategy used in our cardiac in-
tensive care unit that may be associated with these improved
outcomes is the early and frequent assessment for readiness
for ECMO decannulation. This approach is perhaps used by
other centers as well, and possibly it represents a change in
the ‘‘philosophy’’ of ECMO and need for ECMO. Though
a life-saving procedure, ECMOcarries an abundance of risks,
and we make every attempt to transition patients off ECMO,
even at the expense of inotropic support.OR-ECMO
The highest survival to hospital discharge, 77%, was
noted in the OR-ECMO group. Some of the relevant factors324 The Journal of Thoracic and Cardiovascular Surgassociated with mortality included lower weight and
a constellation of parameters that are probably linked to
each other. These included higher ECMO flows at 4 and
24 hours and decreased ventricular function and increased
inotropic support after decannulation. In addition, nonsurvi-
vors had longer ECMO duration and significantly more
complications including intracranial hemorrhage. Inas-
much as this was a surgical group, we also looked at the in-
cidence of residual cardiac defects and found only 1 (3%)
patient who required surgical reintervention.
Published single-center reports show that the overall hos-
pital survival for patients who fail to separate from CPB is
around 47% with a range from 35% to 61%.1,6,11-18
Beyond some of the risk factors already mentioned under
the E-CPR section, the presence of hemodynamically signif-
icant residual cardiac defects is associated with poor sur-
vival.1,11,15,19 In the recent study by Alsoufi and
coworkers,11 37% of the patients required ECMO for failure
to separate from CPB and, among these, 20% required redo
cardiac surgery with only 24% surviving to hospital dis-
charge. In another study by Morris and coworkers,1 which
included 13 patients for failure to separate from CPB,
54% required redo cardiac surgery. In general, significant
residual cardiac lesions are poorly tolerated after cardiac
surgery and thus weaning from ECMOmay not be possible.
Another explanation, however, for the higher survival in
this study is the possibility of lower threshold for placing pa-
tients onECMO. Inasmuch aswe do not have the exact intra-
operative data, it is conceivable that perhaps a ‘‘slower’’
wean from CPB with more inotropic agents might have
avoided the use of ECMO.
LCOS-ECMO
The lowest survival, 62.5%, was noted in the LCOS-
ECMO group. Nonsurvivors in this group had significantly
more chromosomal and noncardiac defects, increased
ECMOflow requirement at 24 hours, increased lactic acido-
sis, and, as with previous groups, more complications
including intracranial bleeding, ECMO circuit thrombi,
and oxygenator failure. It is unclear why this group appeared
to have had more circuit thrombi and oxygenator failures,
but perhaps this is related to anticoagulation inconsistencies.
However, inasmuch as we did not collect data on anticoagu-
lation, we cannot be certain. Anecdotally, though, after our
program converted to Quadrox oxygenators we witnessed
fewer failures. The lower survival in this group was rather
surprising, particularly when the main objective of deploy-
ing ECMO in these patients was to prevent possible cardiac
arrest and therefore improve survival. Compared with the
other 2 groups, it appeared that these patients had a tendency
toward longer ECMOcourse and had higher 24-hour ECMO
flows. These factors perhaps indicate an underlying signifi-
cant myocardial dysfunction that precluded ECMO decan-
nulation. In addition, however, this group seemed to haveery c August 2013
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monary complications, lower lung compliance, and more
hemolysis. It is difficult to concludewhether all these events
were secondary to possible ongoingmyocardial dysfunction
and longer ECMO course or whether they occurred owing to
‘‘prolonged’’ LCOS and perhaps earlier ECMO deployment
would have prevented them. It is also possible that merely
having more patients with chromosomal and other noncar-
diac structural defects predisposed this group to more com-
plications and higher mortality.
Complications
Despite our aggressive laboratory and imaging monitor-
ing, we still witnessed a fair number of complications
that, to an extent, appear to be associated with our mortality.
Although we are constantly reevaluating and improving our
ECMOmanagement protocol, it is not realistic to expect no
complications in such a nonphysiologic circulation. There-
fore, a strong effort should always be made to shorten
ECMO duration when possible.
Neurodevelopmental Outcomes
Neurologic injury after ECMO and particularly after
E-CPR is one of the most concerning and well-documented
complications.20 The incidence, however, varies among insti-
tutions. This is partly because of how neurologic injury is de-
fined from study to study, which can include acute clinical
symptoms, functional outcomes, or any radiologic evidence.
In our study, the overall incidence of acute neurologic injury
was 22%, which is comparable with the incidence reported
byBarrett and colleagues21 in E-CPRpatients. From a neuro-
developmental standpoint, in the intermediate-term, 89% of
the survivors had either normal assessment or only mild dis-
ability. Although the POPC scale used in this study is limited
because it lacks detailed assessment of intelligence and cog-
nitive function, this scale has been shown to predict perfor-
mance in the more meticulous psychometric testing.9
Nevertheless, standardized comprehensive neuropsycho-
logic testing is of paramount importance in all these patients
andwe are currently in the process of evaluating all survivors.
CONCLUSIONS
ECMOwas successfully used in childrenwith cardiac dis-
ease, with 73% and 66% short- and intermediate-term sur-
vival, respectively, with the majority of the survivors
having normal or only minimal neurodevelopmental deficit.
A sustained, interdisciplinary team of cardiothoracic sur-
geons, cardiac intensivists, and perfusionists that is able to
adopt and continuously improve on the peri-ECMOmanage-
ment approach with strict protocols is vital to this success.
References
1. Morris MC, Ittenbach RF, Godinez RI, Portnoy JD, Tabbutt S, Hanna BD, et al.
Risk factors for mortality in 137 pediatric cardiac intensive care unit patientsThe Journal of Thoracic and Camanaged with extracorporeal membrane oxygenation. Crit Care Med. 2004;
32:1061-9.
2. Alsoufi B, Al-Radi OO, Gruenwald C, Lean L, Williams WG, McCrindle BW,
et al. Extra-corporeal life support following cardiac surgery in children: analysis
of risk factors and survival in a single institution. Eur J Cardiothorac Surg. 2009;
35:1004-11.
3. Kane DA, Thiagarajan RR,Wypij D, Scheurer MA, Fynn-Thompson F, Emani S,
et al. Rapid-response extracorporeal membrane oxygenation to support cardio-
pulmonary resuscitation in children with cardiac disease. Circulation. 2010;
122(11 Suppl):S241-8.
4. Thiagarajan RR, Laussen PC, Rycus PT, Bartlett RH, Bratton SL. Extracorporeal
membrane oxygenation to aid cardiopulmonary resuscitation in infants and chil-
dren. Circulation. 2007;116:1693-700.
5. Chan T, Thiagarajan RR, Frank D, Bratton SL. Survival after extracorporeal car-
diopulmonary resuscitation in infants and children with heart disease. J Thorac
Cardiovasc Surg. 2008;136:984-92.
6. Delmo Walter EM, Alexi-Meskishvili V, Huebler M, Loforte A, Stiller B,
Weng Y, et al. Extracorporeal membrane oxygenation for intraoperative cardiac
support in children with congenital heart disease. Interact Cardiovasc Thorac
Surg. 2010;10:753-8.
7. Hannan RL, Ojito JW, Ybarra MA, O’Brien MC, Rossi AF, Burke RP. Rapid car-
diopulmonary support in children with heart disease: a nine-year experience. Ann
Thorac Surg. 2006;82:1637-41.
8. Jacobs JP, Lacour-Gayet FG, JacobsML,ClarkeDR,TchervenkovCI,Gaynor JW,
et al. Initial application in theSTScongenital database of complexity adjustment to
evaluate surgical case mix and results. Ann Thorac Surg. 2005;79:1635-49.
9. Fiser DH, Long N, Roberson PK, Hefley G, Zolten K, Brodie-Fowler M. Rela-
tionship of pediatric overall performance category and pediatric cerebral perfor-
mance category scores at pediatric intensive care unit discharge with outcome
measures collected at hospital discharge and 1- and 6-month follow-up assess-
ments. Crit Care Med. 2000;28:2616-20.
10. Raymond TT, Cunnyngham CB, Thompson MT, Thomas JA, Dalton HJ,
Nadkarni VM. American Heart Association National Registry of CPR Investiga-
tors. Outcomes among neonates, infants, and children after extracorporeal car-
diopulmonary resuscitation for refractory inhospital pediatric cardiac arrest:
a report from the National Registry of Cardiopulmonary Resuscitation. Pediatr
Crit Care Med. 2010;11:362-71.
11. Alsoufi B, Al-Radi OO, Nazer RI, Gruenwald C, Foreman C,WilliamsWG, et al.
Survival outcomes after rescue extracorporeal cardiopulmonary resuscitation in
pediatric patients with refractory cardiac arrest. J Thorac Cardiovasc Surg. 2007;
134:952-9.
12. Walters HL 3rd, Hakimi M, Rice MD, Lyons JM, Whittlesey GC, Klein MD. Pe-
diatric cardiac surgical ECMO: multivariate analysis of risk factors for hospital
death. Ann Thorac Surg. 1995;60:329-36.
13. Jaggers JJ, Forbess JM, Shah AS, Meliones JN, Kirshbom PM, Miller CE, et al.
Extracorporeal membrane oxygenation for infant postcardiotomy support: sig-
nificance of shunt management. Ann Thorac Surg. 2000;69:1476-83.
14. Aharon AS, Drinkwater DC Jr, Churchwell KB, Quisling SV, Reddy VS,
Taylor M, et al. Extracorporeal membrane oxygenation in children after repair
of congenital cardiac lesions. Ann Thorac Surg. 2001;72:2095-101.
15. Kolovos NS, Bratton SL, Moler FW, Bove EL, Ohye RG, Bartlett RH, et al. Out-
come of pediatric patients treated with extracorporeal life support after cardiac
surgery. Ann Thorac Surg. 2003;76:1435-41.
16. Chaturvedi RR, Macrae D, Brown KL, Schindler M, Smith EC, Davis KB, et al.
Cardiac ECMO for biventricular hearts after paediatric open heart surgery.Heart.
2004;90:545-51.
17. Alsoufi B, Shen I, Karamlou T, Giacomuzzi C, Burch G, Silberbach M, et al. Extra-
corporeal life support inneonates, infants, andchildrenafter repair of congenital heart
disease: modern era results in a single institution. Ann Thorac Surg. 2005;80:15-21.
18. Thourani VH, Kirshbom PM, Kanter KR, Simsic J, Kogon BE, Wagoner S, et al.
Venoarterial extracorporeal membrane oxygenation (VA-ECMO) in pediatric
cardiac support. Ann Thorac Surg. 2006;82:138-44.
19. Black MD, Coles JG,WilliamsWG, Rebeyka IM, Trusler GA, Bohn D, et al. De-
terminants of success in pediatric cardiac patients undergoing extracorporeal
membrane oxygenation. Ann Thorac Surg. 1995;60:133-8.
20. Cengiz P, Seidel K, Rycus PT, Brogan TV, Roberts JS. Central nervous system
complications during pediatric extracorporeal life support; incidence and risk
factors. Crit Care Med. 2005;33:2817-24.
21. Barrett CS, Bratton SL, Salvin JW, Laussen PC, Rycus PT, Thiagarajan RR. Neu-
rological injury after extracorporeal membrane oxygenation use to aid pediatric
cardiopulmonary resuscitation. Pediatr Crit Care Med. 2009;10:445-51.rdiovascular Surgery c Volume 146, Number 2 325
